natgillin/translations-raw huggingface dataset:
Docetaxel Winthrop must not be used in people who are hypersensitive (allergic) to docetaxel or any of the other ingredients.
Zdravila Docetaxel Winthrop ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) docetaksel ali katero koli drugo sestavino zdravila.
Docetaxel Winthrop should be used in wards specialising in chemotherapy (using medicines to treat cancer) under the supervision of a doctor who is qualified in the use of chemotherapy.
Zdravilo Docetaxel Winthrop je treba uporabljati na specializiranih oddelkih za kemoterapijo (kjer se uporabljajo zdravila proti raku) in se sme dajati le pod nadzorom zdravnika, usposobljenega za uporabo kemoterapije.
Docetaxel Winthrop was administered as a 1-hour infusion, all other medicinal products were given intraveinously on day 1 every three weeks.
Zdravilo Docetaxel Winthrop je bilo uporabljeno v 1-urni infuziji, vsa druga zdravila pa intravensko 1. dan na tri tedne.
Docetaxel Winthrop will be administered to you by a healthcare professional.
Zdravilo Docetaxel Winthrop vam bo dal pristojni zdravstveni delavec.
Docetaxel Winthrop will be given by infusion into one of your veins (intravenous use).
Zdravilo Docetaxel Winthrop boste dobili v infuziji v eno od ven (intravenska uporaba).
Docetaxel3
docetaksel3
Doctor Phone: Patient Code number:
Ime zdravnika: Tel. št. zdravnika: Številka bolnika:
Doctor's Name:
Zdravnikovo ime:
Doctor/Hospital Address
Naslov zdravnika/bolnišnice
Doctor: .......................……………… Tel: ...................……………………………………………..
Zdravnik: .......................……………… Tel: ...................……………………………………………..
Doctor: .......................……………… Tel: ...................……………………………………………..
Zdravnik: .......................……………… Tel:...................……………………………………………..
Doctor:.......................…………………… Tel:...................…………
Zdravnik: .......................…………………… Tel. št.: ...................
Doctor:.......................…………………… Tel:...................…………
Zdravnik:………………………………… Tel.:……………………..
Doctor:.......................……………………………………………
Zdravnik: .......................
Doctors are aware of this possibility and have emergency treatment available for use in such cases.
Zdravniki vedo, da se to lahko zgodi, in imajo za takšne primere na voljo zdravila za nujno uporabo.
Doctors can also be provided with a home administration training pack, which includes materials for doctors on how to train patients who will inject themselves with Nplate at home, and materials for patients on how to prepare the medicine for injection.
Zdravniki bodo prejeli tudi komplet za usposabljanje za uporabo zdravila na domu, ki vsebujejo gradivo za zdravnike o tem, kako usposobiti bolnike, ki si bodo zdravilo Nplate sami injicirali doma, ter gradivo za bolnike o tem, kako pripraviti zdravilo za injiciranje.
Doctors may recommend a lower dose or a break from treatment if these values change or if patients have certain side effects.
Če se te vrednosti spremenijo ali pa se pri bolnikih pokažejo določeni neželeni učinki, lahko zdravniki priporočijo nižji odmerek ali prekinitev zdravljenja.
Doctors must be careful when switching patients who are at risk of developing hypoglycaemia (low blood sugar levels) to Avaglim, such as elderly patients, patients with low weight or those who have been taking certain other medicines.
Zdravniki morajo biti previdni, kadar preidejo na zdravilo Avaglim pri bolnikih, pri katerih obstaja nevarnost za hipoglikemijo (nizko raven sladkorja v krvi), kot so na primer starejši bolniki, bolniki z nizko telesno težo ali bolniki, ki jemljejo nekatera druga zdravila.
Doctors prescribing Leflunomide Winthrop need to be aware of the risk of liver problems associated with the medicine.
Zdravniki, ki predpisujejo zdravilo Leflunomide Winthrop, se morajo zavedati tveganja za težave z jetri, ki je povezano s tem zdravilom.
Doctors prescribing this medicine must have experience with methotrexate and understand how it works.
Zdravniki, ki predpisujejo to zdravilo, morajo imeti izkušnje z metotreksatom in razumeti, kako deluje.
Doctors shall be encouraged also to enrol patients with familial LPLD who are not treated with Glybera.
Zdravnike bodo spodbujali, da v register vključijo tudi bolnike z družinskim LPLD, ki se niso zdravili z zdravilom Glybera.
Doctors should also periodically assess patients with chronic ITP who still have a spleen to see if they require surgery.
Bolnike s kronično imunsko trombocitopenično purpuro, ki še imajo vranico, morajo zdravniki redno ocenjevati, da bi ugotovili, ali potrebujejo kirurški poseg.
Doctors should check the patient’s liver before starting treatment with Tasmar and then regularly during treatment.
Zdravniki morajo pregledati bolnikova jetra pred začetkom zdravljenja z zdravilom Tasmar ter nato redno med samim zdravljenjem.
Doctors should make decisions on whether to use Ebilfumin in babies of this age based on the severity of the disease caused by the flu virus and the baby’s state of health, to ensure that the baby is likely to benefit from the medicine.
Da se zagotovi, da bo dojenčku zdravilo Ebilfumin koristilo, morajo zdravniki na podlagi resnosti bolezni, ki jo povzroči virus gripe, in dojenčkovega zdravstvenega stanja presoditi, ali pri dojenčkih te starosti uporabiti zdravilo Ebilfumin.
Doctors should monitor kidney function carefully in patients with moderately or severely reduced kidney function.
Pri bolnikih z zmernim ali zelo zmanjšanim delovanjem ledvic mora zdravnik njihovo delovanje skrbno spremljati.
Doctors should monitor patients carefully for signs of infection during treatment, and should prescribe RoActemra with caution in patients who have had recurring or long-term infections, or diseases that could increase the risk of infections, such as diverticulitis (a disease affecting the gut) or diabetes.
Zdravniki morajo bolnike med zdravljenjem z zdravilom RoActemra pozorno spremljati zaradi znakov okužb in ga predpisovati previdno pri bolnikih s ponavljajočimi ali dolgotrajnimi okužbami ali boleznimi, ki bi lahko povečale tveganje za pojav okužb, kakršni sta divertikulitis (bolezen, ki prizadene črevesje) ali sladkorna bolezen.
Doctors should monitor patients for fluid retention as this can lead to heart failure (an inability of the heart to pump enough blood around the body).
Zdravniki morajo bolnike nadzorovati glede zadrževanja tekočine, saj lahko to privede do srčnega popuščanja (nesposobnost srca, da prečrpa dovolj krvi po telesu).
Doctors should prescribe Telzir to patients who have already taken medicines belonging to the same class as Telzir (protease inhibitors) only after they have looked at the antiviral medicines the patient has taken before and considered the likelihood that the virus will respond to the medicine.
Zdravniki lahko zdravilo Telzir predpišejo bolnikom, ki so že jemali zdravila iz razreda, v katerem je zdravilo Telzir (zaviralci proteaz), šele ko preverijo protivirusna zdravila, ki jih je posameznik prejemal že prej, in ocenijo verjetnost, da se bo virus odzval na zdravilo.
Doctor’s name:
Zdravnikovo ime:
Doctor’s office telephone and e-mail:
Telefon ali e-pošta zdravnikove ordinacije:
Doctor’s phone:
Zdravnikov telefon:
Document revision date:
Datum zadnje revizije besedila:
Documentation
Skráning
documentation of childbearing potential status
dokumentacijo o statusu plodnosti
Documentation on the safety and efficacy of busulfan in combination with cyclophosphamide in the BuCy2 regimen prior to conventional allogeneic and/or autologous HPCT derives from two clinical trials (OMC-BUS-4 and OMC-BUS-3).
Dokumentacija o varnosti in učinkovitosti busulfana v kombinaciji s ciklofosfamidom v terapiji BuCy2 pred konvencionalno alogensko in/ali avtologno HPCT izhaja iz dveh kliničnih preskušanj (OMC-BUS- 4 in OMC-BUS-3).
Does not contain a tablet
Ne vsebuje tablete.
Does not contain any tablets
Ne vsebuje tablet.
does not make enough insulin to control the level of sugar in your blood or is not able to use the insulin properly.
da proizvede dovolj insulina za zadostno uravnavanje koncentracije krvnega sladkorja ali da pravilno izkoristi v telesu nastali insulin.
Does not require any special storage conditions.
Za shranjevanje zdravila niso potrebna posebna navodila.
Dofetilide  (Not studied, potential increase via inhibition of OCT2 transporter)
dofetilid  (Ni raziskano; morebitno povišanje preko zaviranja prenašalca OCT2)
Dog and cats
Psi in mačke
Dog body-weight in kg
Tel. masa psa v kg
Dog Cat4
pes maček4
Dog Weight (kg)
Psi Teža (kg)
Dog4 Cat4
pes4 maček4
Dog: Vaccination during and after VIRBAGEN OMEGA treatment is contra-indicated, until the dog appears to have recovered.
Psi: cepljenje med in po terapiji z zdravilom VIRBAGEN OMEGA je kontraindicirano, dokler se ne zdi, da je pes okreval.
Dogs
pes
Dogs (bitches)
Psi (psice)
Dogs (male) and ferrets (male)
Psi (samci) in beli dihurji (samci).
dogs 10-20 kg
psi 10–20 kg
dogs 2-10 kg
psi 2–10 kg
Dogs 2-10 kg Dogs 10-20 kg Dogs 20-40 kg Dogs 40-60 kg
Psi 2–10 kg Psi 10–20 kg Psi 20–40 kg Psi 40–60 kg
dogs 20-40 kg
psi 20–40 kg
Dogs 2–3.5 kg Dogs >3.5–7.5 kg Dogs >7.5–15 kg Dogs >15–30 kg Dogs >30–60 kg
Psi 2 ̶ 3,5 kg Psi >3,5 ̶ 7,5 kg Psi >7,5–15 kg Psi >15–30 kg Psi >30–60 kg
dogs 40-60 kg
psi 40–60 kg
Dogs aged 12 months or more.
Psi, stari 12 mesecev in več.
Dogs and cats
Psi in mačke.
Dogs and cats
Psi, mačke
Dogs and cats: 8 mg cefovecin/kg body weight (1 ml/10 kg body weight).
Psi in mačke: 8 mg cefovecina/ kg telesne teže (1 ml/10 kg telesne teže).
Dogs and cats: it was shown that strict compliance with the recommended posology is compulsory to achieve clinical benefit.
Psi in mačke: Da se doseže primeren klinični učinek je potrebno natančno upoštevati priporočeno odmerjanje.
Dogs and cats: it was shown that strict compliance with the recommended posology is compulsory to achieve clinical benefit.
Psi in mačke: Da se doseže primeren klinični učinek, je potrebno natančno upoštevati priporočeno odmerjanje.
Dogs and cats: The safety of the veterinary medicinal product has not been established during pregnancy and lactation (See section 4.3).
Psi in mačke: Varnost zdravila v obdobju brejosti in laktacije ni bila ugotovljena (glejte poglavje 4.3).
Dogs and cats: The safety of the veterinary medicinal product has not been established during pregnancy and lactation.
Psi in mačke: Varnost veterinarskega zdravila ni bila ugotovljena za obdobje brejosti in laktacije.
Dogs from 1.5 to 4 kg body weight
Psi 1.5 to 4 kg telesne teže
Dogs in areas endemic for heartworm, or those which have travelled to endemic areas, may be infected with adult heartworms.
Psi, ki se nahajajo na področju, kjer se nahajajo prenašalci teh zajedavcev in psi, ki na tako področje potujejo, se lahko infestirajo z Dirofilario immitis.
Dogs in areas endemic for heartworm, or those which have travelled to endemic areas, may be infected with adult heartworms.
Psi, ki se nahajajo na področju, kjer se nahajajo prenašalci teh zajedavcev in psi, ki na tako področje potujejo, se lahko infestirajo z odraslo obliko Dirofilarie immitis.
Dogs in the household should only be treated with a veterinary medicinal product authorised for use in that species.
Pse v istem gospodinjstvu je potrebno tretirati samo s sredstvom za uporabo v veterinarski medicini, ki je ustrezno za uporabo pri psih.
Dogs infected with adult heartworms tolerated up to 5 times the recommended dose, every 2 weeks for 3 treatments, without any adverse effects.
Psi, ki so bili inficirani z Dirofilario immitis so dobro prenašali petkratni terapevtski odmerek vsak drugi teden po trikratnem nanosu.
Dogs infected with adult heartworms tolerated up to 5 times the recommended dose, every 2 weeks for 3 treatments, without any adverse effects.
Psi, ki so bili inficirani z Dirofilario immitis so dobro prenašali petkratni terapevtski odmereke vsak drugi teden po trikratnem nanosu.
Dogs less than 5 kg Dogs 5 to 10 kg Dogs 10 to 20 kg Dogs 20 to 40 kg Dogs 40 to 60 kg
Psi lažji od 5 kg Psi 5 do 10 kg Psi 10 do 20 kg Psi 20 do 40 kg Psi 40 do 60 kg
Dogs may very rarely show short-lived redness, itching or other signs of discomfort at the application site.
V zelo redkih primerih se lahko pri psih pojavijo kratkotrajna rdečica, srbenje ali drugi znaki neudobja na mestu nanosa.
Dogs may very rarely vomit or have diarrhoea.
V zelo redkih primerih se lahko pri psih pojavi bruhanje ali driska.
Dogs Oral use Blister (Alu/Alu)
Pretisni omot
Dogs over 10 kg and up to 40 kg body weight
Psi nad 10 kg in do 40 kg telesne teže
Dogs over 4 kg and up to 10 kg body weight
Psi nad 4 kg in do 10 kg telesne teže
Dogs over 40 kg body weight
Psi nad 40 kg telesne teže
Dogs receiving APOQUEL tablets should therefore be monitored for the development of infections and neoplasia.
Zato je pse, ki prejemajo tablete APOQUEL, potrebno spremljati glede pojava okužb in neoplazij.
Dogs should be carefully monitored for signs of (haemolytic) anaemia.
Pse je treba skrbno spremljati glede znakov (hemolitične) anemije.
Dogs should be carefully observed following administration to ensure that each tablet is swallowed.
Po dajanju zdravila pozorno opazujte psa, da se prepričate, da je pogoltnil (vsako) tableto.
Dogs should be dosed daily.
Psom je treba dajati dnevne odmerke.
Dogs should not be bathed or shampooed from 48 hours before treatment.
Psov ne kopamo in ne šamponiramo 48 ur pred nanosom zdravila.
Dogs weighing 10.1–20.0 kg.
Psi s telesno maso 10,1–20,0 kg.
Dogs weighing 2.6–5.0 kg.
Psi s telesno maso 2,6–5,0 kg.
Dogs weighing 20.1–40.0 kg.
Psi s telesno maso 20,1–40,0 kg.
Dogs weighing 40.1–60.0 kg.
Psi s telesno maso 40, 1–60,0 kg.
Dogs weighing 5.1–10.0 kg.
Psi s telesno maso 5,1–10,0 kg.
Dogs weighing less than 2 kg, apply 2 drops to the ear once a day.
Psom s telesno maso manj kot 2 kg dajemo 2 kapljici zdravila v sluhovod enkrat dnevno.
Dogs with Addison’s disease have insufficient levels of aldosterone in their blood and Zycortal is used to replace the missing hormone.
Psi z Addisonovo boleznijo nimajo zadostnih ravni aldosterona v krvi in zdravilo Zycortal se uporablja za nadomeščanje manjkajočega hormona.
Dogs, Cats
Psi, ma ke. č
Dogs, cats, cattle (calves and young cattle) and pigs
Psi, mačke, govedo (teleta in mlado govedo) in prašiči
Dogs, cats, horses
Psi, mačke, konji
Dogs, ferrets
Psi in beli dihurji
Dogs: i.v. or s.c.
Psi: i.v. ali s.c.
Dogs: In cases of overdosage, or if the effects of dexmedetomidine become potentially life- threatening, the appropriate dose of atipamezole is 10 times the initial dose of dexmedetomidine (micrograms/ kg bw or micrograms/ square meter body surface area).
Psi: V primeru prevelikega odmerjanja, ali če postanejo učinki deksmedetomidina potencialno nevarni za življenje, uporabite odmerek atipamezola, 10-krat večji od prvotnega odmerka deksmedetomidina (v mikrogramih/kg telesne teže ali mikrogramih/kvadratni meter telesne površine).
Dogs: Intravenous
Psi: Intrakavenska uporaba
Dogs: intravenous or intramuscular use
Psi: intravenska ali intramuskularna uporaba
Dogs: intravenous or intramuscular use Cats: intramuscular use
Psi: intravenska ali intramuskularna uporaba Mačke: intramuskularna uporaba
Dogs: intravenous or intramuscular use Cats: intramuscular use
Psi: intravenska in intramuskularna uporaba Mačke: intramuskularna uporaba
Dogs: intravenous or subcutaneous Cats: subcutaneous
Psi: intravenska podkožna, Mačke: Podkožna
Dogs: intravenous or subcutaneous use Cats: subcutaneous use
Psi: intravensko ali subkutano dajanje Mačke: subkutano dajanje
Dogs: Intravenous route Cats: Subcutaneous route
Psi: intravenska uporaba Mačke: subkutana uporaba
Dogs: IV or SC
Psi: i.v. ali s.c.
Dogs: IV or SC Cats: SC
Psi: IV ali SC Mačke: SC
Dogs: IV or SC.
Psi: i.v. ali s.c.
Dogs: No adverse reactions other than those described in section 4.6 have been observed following subcutaneous administration of up to 6 times the recommended dose.
Psi: Pri subkutanem dajanju do 6-kratnega priporočenega odmerka niso opazili neželenih učinkov, razen tistih, opisanih v poglavju 4.6.
Dogs: No adverse reactions other than those described in section “Adverse effects” have been observed following subcutaneous administration of up to 6 times the recommended dose.
Psi: Pri subkutanem dajanju do 6-kratnega priporočenega odmerka, niso opazili neželenih učinkov, razen tistih, opisanih v poglavju »Neželeni učinki«.
Dogs: The recommended dose is 15 mg indoxacarb/kg body weight, equivalent to 0.077 ml/kg body weight.
Psi: Priporočeni odmerek je 15 mg indoksakarba/kg telesne teže, kar ustreza 0,077 ml/kg telesne teže.
Dogs: Vaccination during and after VIRBAGEN OMEGA treatment is contra-indicated, until the dog appears to have recovered.
Psi: cepljenje med in po terapiji z VIRBAGEN OMEGA je kontraindicirano, dokler se ne zdi, da je pes okreval.
Dog’s weight
Teža psa
Doing so could increase the risk of the virus developing resistance.
Če bi zdravljenje prekinili, bi povečali možnost, da virus postane odporen na zdravila.
dolutegravir
lopinavir/ritonavir.
Dolutegravir
odmerka
Dolutegravir (50 mg once daily)/ sofosbuvir/ velpatasvir (400/ 100 mg once daily)
Dolutegravir (50 mg enkrat na dan)/sofosbuvir/velpatasvir (400/100 mg enkrat na dan)
Dolutegravir 50 mg +
Dolutegravir 50 mg + ABC/3TC
Dolutegravir 50 mg once daily (daclatasvir 60 mg once daily)
Dolutegravir 50 mg enkrat na
Dolutegravir 50 mg Once Daily + 2 NRTI N=411
Dolutegravir 50 mg enkrat na dan +
Dolutegravir and other suspect agents should be discontinued immediately if signs or symptoms of hypersensitivity reactions develop (including, but not limited to, severe rash or rash accompanied by raised liver enzymes, fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, facial oedema, eosinophilia, angioedema).
Če se pojavijo znaki ali simptomi preobčutljivostnih reakcij (vključno, vendar ne izključno, hud izpuščaj ali izpuščaj v povezavi s povišanimi vrednostmi jetrnih encimov, zvišana telesna temperatura, splošno slabo počutje, utrujenost, bolečine v mišicah ali sklepih, mehurji, ustne lezije, konjunktivitis, obrazni edem, eozinofilija, angioedem), je treba uporabo dolutegravirja in drugih zadevnih zdravil takoj ukiniti.
Dolutegravir belongs to a group of anti-retroviral medicines called integrase inhibitors (INIs).
Dolutegravir spada v skupino protiretrovirusnih zdravil, ki se imenujejo zaviralci integraze (INIs – integrase inhibitors).
dolutegravir can be used without
dolutegravir se lahko uporablja brez
dolutegravir can be used without dose adjustment.
dolutegravir se lahko uporablja brez
Dolutegravir did not affect male or female fertility in rats at doses up to 1000 mg/kg/day, the highest dose tested (24 times the 50 mg twice daily human clinical exposure based on AUC).
Dolutegravir pri podganah v odmerkih do 1000 mg/kg/dan ni vplival na plodnost samcev ali samic; odmerek 1000 mg/kg/dan je bil največji testirani odmerek (24-kratnik klinične izpostavljenosti pri človeku med uporabo 50 mg dvakrat na dan, na podlagi AUC).
Dolutegravir had no pharmacodynamic effect on
Dolutegravir ni imel farmakodinamičnega učinka
Dolutegravir has a <10 fold change against 94% of the 705 clinical isolates.
Dolutegravir ima <10 spremembe občutljivosti proti 94% od 705 kliničnih izolatov.
dolutegravir is 50 mg twice daily when
dolutegravir 
dolutegravir is 50 mg twice daily when co-administered with carbamazepine, DTG/ABC/3TC FDC is not recommended for patients taking carbamazepine.
Ker je pri sočasnem dajanju z rifampicinom odmerek dolutegravirja 50 mg dvakrat dnevno, se sočasna
Dolutegravir is also a substrate of UGT1A3, UGT1A9, CYP3A4, P-gp, and BCRP.
Dolutegravir je tudi substrat za UGT1A3, UGT1A9, CYP3A4, P-gp in BCRP.
Dolutegravir is also a substrate of UGT1A3, UGT1A9, CYP3A4, Pgp, and BCRP; therefore medicinal products that induce those enzymes may decrease dolutegravir plasma concentration and reduce the therapeutic effect of dolutegravir (see Table 1).
Dolutegravir je tudi substrat za UGT1A3, UGT1A9, CYP 3A4, Pgp in BCRP, zato lahko zdravila, ki inducirajo te encime, znižajo plazemske koncentracije dolutegravirja in zmanjšajo njegov terapevtski učinek (glejte Preglednico 1).
Dolutegravir is present in cerebrospinal fluid (CSF).
Dolutegravir je prisoten v cerebrospinalni tekočini (CSF – cerebrospinal fluid).
Dolutegravir is primarily metabolized through glucuronidation via UGT1A1 with a minor CYP3A component.
Dolutegravir se presnavlja predvsem preko glukuronidacije z UGT1A1 in v majhni meri s CYP3A.
Dolutegravir is the predominant circulating compound in plasma; renal elimination of unchanged active substance is low (< 1% of the dose).
Dolutegravir je prevladujoča snov, ki kroži v plazmi; izločanje nespremenjene zdravilne učinkovine preko ledvic je majhno (< 1 % odmerka).
Dolutegravir may increase plasma concentrations of medical products in which excretion is dependent upon OAT3.
Dolutegravir lahko poviša plazemske koncentracije zdravil, katerih izločanje je odvisno od OAT3.
Dolutegravir should be used during pregnancy only if the expected benefit justifies the potential risk to the foetus.
Dolutegravir naj se med nosečnostjo uporablja samo, če pričakovane koristi odtehtajo morebitno tveganje za plod.
Dolutegravir should not be used with etravirine without co- administration of atazanavir/ritonavir, darunavir/ritonavir or lopinavir/ritonavir in INI- resistant patients (see further below in table).
Dolutegravir se ne sme uporabljati z etravirinom brez sočasne uporabe atazanavirja/ritonavirja, darunavirja/ritonavirja ali lopinavirja/ritonavirja pri bolnikih odpornih proti zaviralcem integraze (glejte v preglednici spodaj).
Dolutegravir 
lopinavir+ritonavir/dolutegravir
Dolutegravir  (Not studied)
dolutegravir  (ni raziskano)
Dolutegravir  (Not studied)
ritonavir
Dolutegravir 
dolutegravir
Dolutegravir 
kationskega prenašalca)
Dolutegravir  (Not studied, a similar reduction in exposure as observed with efavirenz is expected, due to induction)
dolutegravir  (Ni raziskano; zaradi indukcije se pričakuje podobno zmanjšanje izpostavljenosti kot pri efavirenzu)
dolutegravir.
dolutegravirja.
Domaniewska 50C 02-672 Warszawa
Centro Empresarial Osa Mayor Avda.
domperidone, a medicine used to treat nausea and vomiting.
domperidon, zdravilo proti slabosti in bruhanju,
domperidone, used to treat nausea and vomiting or to stimulate breast milk production. methadone, used to treat pain.
domperidon, ki se uporablja za zdravljenje slabosti in bruhanja ali za spodbujanje nastajanja mleka v dojki metadon, ki se uporablja za zdravljenje bolečine
Domperidone: AUC: ↑ 3.0 fold
Domperidon: AUC: ↑ 3,0-krat
Dompé
Amgen
Don't stop taking Volibris without your doctor's advice
Ne prenehajte z jemanjem zdravila Volibris, razen če vam tako svetuje vaš zdravnik.
Don't take Tivicay with the following medicine: dofetilide, used to treat heart conditions
Ne jemljite zdravila Tivicay z naslednjimi zdravili: dofetilid, ki se uporablja za zdravljenje bolezni srca
Don't take Triumeq with the following medicine: dofetilide, used to treat heart conditions
Ne jemljite zdravila Triumeq z naslednjim zdravilom: dofetilid, ki se uporablja za zdravljenje bolezni srca
Don't transfer it to any other container.
Zdravila Norvir ne prelivajte v noben drug vsebnik.
done when co-administration
uporabi z okrepljenim zdravilom
done when co-administration
uporabi z zdravilom PREZISTA skupaj z
Donors who receive G-CSFs for PBPC mobilisation should be monitored until haematological indices return to normal.
Darovalce, ki za zbiranje matičnih celic iz periferne krvi prejemajo faktor, ki spodbuja rast granulocitnih kolonij (G–CSF), je potrebno spremljati, dokler ne dobimo normalne hematološka slike.
Don’t
Nikoli ne smete
Don’t block the air vent with your fingers.
Ne prekrivajte rež za zrak s prsti.
Don’t breast-feed while taking Votrient.
Med zdravljenjem z zdravilom Votrient ne smete dojiti.
Don’t breast-feed while you are taking Avaglim.
Med jemanjem zdravila Avaglim ne smete dojiti.
Don’t breast-feed while you are taking Avandamet.
Med jemanjem zdravila Avandamet ne smete dojiti.
Don’t breast-feed while you are taking Avandia.
Med jemanjem zdravila Avandia ne smete dojiti.
Don’t breast-feed while you are taking Revolade.
Med zdravljenjem z zdravilom Revolade ne smete dojiti.
Don’t breathe out into the inhaler.
Ne izdihnite v inhalator.